Thomas Wynn
Seminars
• How can expanding the target space beyond the common splice modulators unlock new opportunities for targeting novel disease areas
• What strategies are enabling the design of chemically diverse scaffolds to overcome current limitations in the ligand design space
• Are we overdependent on nonsense-mediated decay and can reducing this reliance drive broaden therapeutic applicability of splice modulators
• What lessons can be drawn from recent investments and platform development to guide future innovation in RNA-targeted small molecules
• Introducing Rgenta’s RNA-targeting small molecule platform and its approach to addressing disease-relevant RNA targets
• Highlighting case studies from lead programs in ACC & Huntington’s disease to showcase platform-driven success in drug discovery
• Sharing insights on generating and refining small molecules as RNA splice modulators, including strategies for modeling splice sites
